Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Third Quarter (Q3) and Nine Months ended 30 September 2012
Issuance Date: 31 October 2012
GSK reported Q3 2012 results characterized by a 5% decline in turnover, driven by demanding prior-year comparisons (specifically Cervarix in Japan and US flu vaccines), product disposals, and continued economic weakness in European markets. Despite the headline decline, underlying sales were broadly in line with the prior year when excluding these specific factors. The company highlighted strong performance in Emerging Markets, Asia Pacific (EMAP), and Consumer Healthcare (excluding divestments).
Key Financial Metrics
| Metric | Q3 2012 | Q3 2011 | 9 Months 2012 | 9 Months 2011 |
|---|---|---|---|---|
| Turnover (£m) | 6,527 | 7,104 | 19,629 | 20,409 |
| Core Operating Profit (£m) | 1,970 | 2,328 | 6,043 | 6,539 |
| Core Operating Margin | 30.2% | 32.8% | 30.8% | 32.0% |
| Core EPS (pence) | 26.5p | 30.6p | 80.2p | 84.4p |
| Total EPS (pence) | 22.9p | 27.6p | 75.0p | 79.4p |
| Net Debt (£m) | 13,867 | 9,497 | 13,867 | 9,497 |
| Adjusted Net Cash Inflow from Ops (£m) | 1,797 | 2,318 | 4,935 | 5,358 |
Note: Growth rates in the source text are primarily presented in Constant Exchange Rate (CER) terms. Q3 2012 Core EPS declined 11% in CER terms.
Material Changes vs. Prior Period
- Revenue Decline: Group turnover fell 5% in Q3 and 2% for the nine months. Excluding prior-year comparisons for Cervarix and US flu vaccines (3 percentage points) and product disposals (2 percentage points), sales were broadly flat.
- Regional Performance:
- Europe: Turnover declined 9% due to austerity measures and price reductions.
- US: Turnover declined 6% (Pharmaceuticals and Vaccines), driven by genericization and discontinued products. Excluding these, sales grew 2%.
- EMAP: Turnover grew 11% (Q3) and 7% (9 months), driven by strong growth in China, Latin America, and the Middle East/Africa.
- Japan: Turnover fell 25% (Q3) due to the completion of the HPV catch-up program for Cervarix. Excluding Cervarix, sales grew 6%.
- Acquisition Impact: GSK acquired Human Genome Sciences (HGS) on 3 August 2012. HGS contributed £23 million in sales post-acquisition but had a negative impact on core operating margin of 0.6 percentage points in the quarter.
- Legal Settlements: The company paid £1.9 billion to settle significant US federal government investigations, which was within existing provisions. This contributed to a net debt increase of £4.2 billion in the quarter.
Guidance, Outlook, and Management Commentary
- Full Year Outlook: GSK expects 2012 sales (CER) to be broadly in line with 2011, absent further deterioration in Europe. Core operating margin is expected to be broadly in line with 2011.
- Tax Rate: The full-year core tax rate is now expected to be approximately 25%, two years ahead of the original target.
- R&D Pipeline: Management highlighted exceptional late-stage pipeline progress, with six Phase III programmes completed in 2012. Filings were made for BRAF, MEK, and Relvar/Breo. Filings for albiglutide, dolutegravir, and a LABA/LAMA combination are expected by year-end.
- Shareholder Returns:
- Dividend: Q3 interim dividend increased 6% to 18p per share.
- Buybacks: Total share repurchases for 2012 are expected to be £2.0–£2.5 billion. Year-to-date repurchases totaled £1.9 billion.
- Cost Management: Combined core SG&A and R&D expenditure was flat in Q3. Additional cost reductions are expected to benefit Q4 earnings relative to Q3.
Investor Verification Checklist
- Underlying Sales Growth: Verify the "broadly in line" sales performance by reviewing the specific adjustments for Cervarix, US flu vaccines, and OTC/Vesicare disposals.
- European Market Exposure: Assess the sustainability of the 9% decline in Europe and the impact of ongoing government austerity measures on pricing and volumes.
- HGS Integration: Monitor the realization of the identified $250 million in cost synergies from the Human Genome Sciences acquisition and the timeline for accretion to earnings (expected neutral in 2013, accretive thereafter).
- Legal Provisions: Review the status of remaining legal and tax disputes, noting the £0.6 billion aggregate provision for legal disputes at 30 September 2012.
- Net Debt Trajectory: Confirm the impact of the £1.9 billion legal settlement and HGS acquisition on the balance sheet, noting the increase in net debt to £13.9 billion.
- Pipeline Execution: Track the regulatory filings and approvals for the six novel medicines mentioned (BRAF, MEK, Relvar/Breo, albiglutide, dolutegravir, LABA/LAMA) as key drivers for future growth.